EP
BCLI

EPIQ Partners’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

EPIQ Partners’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-792
Closed -$46K – 92
2021
Q1 		$46K Buy
792
+89
+13% +$6.72K 0.03% 84
2020
Q4 		$48K Buy
+703
New +$95.7K 0.03% 77

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

EPIQ Partners's BCLI Position: Q2 2021 in Review

EPIQ Partners sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2021, closing a stake of 792 shares — an estimated $46K sold.

EPIQ Partners first reported a position in BCLI in Q4 2020 and held it in 2 quarters. The position peaked at $48K in Q4 2020. 57 funds tracked by Wall St. Rank hold BCLI as of Q2 2021.

  • EPIQ Partners reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2021 after selling out during the quarter.
  • EPIQ Partners sold 792 BRAINSTORM CELL THERAPUTC shares in Q2 2021, an estimated $46K.
  • EPIQ Partners first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2020 and held it in 2 quarters.
  • EPIQ Partners's BRAINSTORM CELL THERAPUTC position peaked at $48K in Q4 2020.
  • 57 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2021.

Based on EPIQ Partners's 13F filing for Q2 2021, filed 2 Aug 2021.